Royal Gold, Inc. (RGLD)

Ligand Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2021
Period Ending	Aug 1, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Jun 30, 2021
Market Capitalization	10,048	8,670	7,946	7,394	6,906	7,486
Market Cap Growth	34.37%	9.11%	7.47%	7.07%	-7.75%	-8.19%
Enterprise Value	9,808	8,554	8,176	7,735	6,857	7,273
Last Close Price	152.64	130.73	118.43	108.95	100.41	108.27
PE Ratio	25.27	26.11	33.19	30.94	25.20	24.74
Forward PE	19.04	21.51	30.08	32.35	35.21	35.21
PS Ratio	13.24	12.16	13.28	12.40	10.70	12.29
PB Ratio	3.13	2.77	2.74	2.69	2.66	2.99
P/TBV Ratio	3.14	2.78	2.75	2.70	2.67	3.01
P/FCF Ratio	27.31	20.31	19.24	-	112.31	31.32
P/OCF Ratio	19.05	16.37	19.11	17.72	14.95	18.39
PEG Ratio	1.01	0.81	2.55	3.24	3.52	3.52
EV/Sales Ratio	12.96	12.00	13.66	12.97	10.63	11.94
EV/EBITDA Ratio	15.92	14.90	17.47	16.57	13.25	14.93
EV/EBIT Ratio	20.54	19.90	26.97	27.27	20.88	23.95
EV/FCF Ratio	26.66	20.04	19.79	-	111.52	30.43
Debt / Equity Ratio	-	0.00	0.09	0.21	-	-
Debt / EBITDA Ratio	-	0.01	0.53	1.22	-	-
Debt / FCF Ratio	-	0.01	0.60	-	-	-
Asset Turnover	0.22	0.21	0.17	0.19	-	0.23
Inventory Turnover	7.72	8.57	8.07	7.80	-	6.33
Quick Ratio	4.49	3.06	2.15	2.69	3.30	5.33
Current Ratio	4.74	3.23	2.31	2.92	3.52	5.71
Return on Equity (ROE)	12.99%	11.02%	8.49%	8.96%	-	12.60%
Return on Assets (ROA)	8.81%	7.96%	5.50%	5.64%	-	7.01%
Return on Capital (ROIC)	9.50%	8.55%	5.86%	5.98%	-	7.43%
Return on Capital Employed (ROCE)	14.10%	13.00%	9.20%	8.20%	12.20%	11.70%
Earnings Yield	3.96%	3.83%	3.01%	3.23%	3.97%	4.04%
FCF Yield	3.66%	4.92%	5.20%	-6.83%	0.89%	3.19%
Dividend Yield	1.19%	1.30%	1.31%	1.33%	-	1.11%
Payout Ratio	28.98%	31.70%	41.17%	38.46%	28.73%	25.15%
Buyback Yield / Dilution	-0.07%	-0.06%	-0.12%	-0.05%	0.00%	0.02%
Total Shareholder Return	1.12%	1.24%	1.19%	1.28%	0.00%	1.13%

Updated Feb 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q